Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

Rhea-AI Summary

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced its participation in Citi's 17th Annual BioPharma Conference on September 7-8, 2022. Chairman and CEO Patrick J. McEnany, along with the management team, will host one-on-one meetings on September 8. Catalyst is dedicated to developing and commercializing innovative medicines for rare diseases, including its recently FDA-approved drug FIRDAPSE® for Lambert-Eaton myasthenic syndrome.

FIRDAPSE is also approved for use in Canada, showcasing Catalyst's commitment to addressing unmet medical needs in rare diseases.

CORAL GABLES, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Citi's 17th Annual BioPharma Conference.

Citi's 17th Annual BioPharma Conference
Date:    September 7-8, 2022
Format:    Catalyst's management will host 1x1 meetings on September 8, 2022

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE^® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

For additional information about the Company, please visit www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2021 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals

FAQ

What is Catalyst Pharmaceuticals' participation in the Citi BioPharma Conference?

Catalyst Pharmaceuticals will participate in Citi's 17th Annual BioPharma Conference on September 7-8, 2022, hosting one-on-one meetings on September 8.

When is the Citi BioPharma Conference taking place?

The Citi BioPharma Conference is scheduled for September 7-8, 2022.

What drug has Catalyst Pharmaceuticals developed for Lambert-Eaton myasthenic syndrome?

Catalyst Pharmaceuticals developed FIRDAPSE® (amifampridine) Tablets for the treatment of Lambert-Eaton myasthenic syndrome.

When was FIRDAPSE approved by the FDA?

FIRDAPSE was approved by the FDA in 2018.

Is FIRDAPSE available in Canada?

Yes, FIRDAPSE is approved for use in Canada for treating adults with Lambert-Eaton myasthenic syndrome.